Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.74) price target on GlaxoSmithKline plc (LON:GSK) in a research report sent to investors on Tuesday. The firm currently has a buy rating on the stock.
Several other equities analysts also recently commented on GSK. UBS AG set a GBX 1,600 ($20.84) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Thursday, April 27th. Deutsche Bank AG set a GBX 1,610 ($20.97) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Tuesday. Morgan Stanley set a GBX 1,700 ($22.14) price objective on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research report on Thursday, July 27th. Liberum Capital reaffirmed a buy rating and set a GBX 1,900 ($24.74) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, July 27th. Finally, Citigroup Inc. reaffirmed a neutral rating and set a GBX 1,700 ($22.14) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, July 25th. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of GBX 1,724 ($22.45).
Shares of GlaxoSmithKline plc (GSK) opened at 1475.00 on Tuesday. The stock’s market cap is GBX 72.10 billion. The firm’s 50-day moving average price is GBX 1,589.13 and its 200-day moving average price is GBX 1,623.61. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/08/12/goldman-sachs-group-inc-the-reiterates-gbx-1900-price-target-for-glaxosmithkline-plc-gsk.html.
The company also recently declared a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.23%.
In other news, insider Victoria Whyte sold 4,820 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($22.05), for a total transaction of £81,602.60 ($106,267.22). Also, insider Patrick Vallance purchased 861 shares of the company’s stock in a transaction dated Friday, July 14th. The shares were purchased at an average price of GBX 1,618 ($21.07) per share, for a total transaction of £13,930.98 ($18,141.66). Over the last quarter, insiders have bought 3,151 shares of company stock worth $5,054,922.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.